LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its participation in the American Epilepsy Society (AES) Annual Meeting taking place December 3 – 7 in Chicago, Illinois. The Company will present seven scientific posters aimed at engaging clinical collaborators and deepening understanding of the LivaNova VNS Therapy^® System for the treatment of drug-resistant epilepsy.

• "The Patient Journey Prior to Neurostimulation in Drug-Resistant Epilepsy." Presented by Reginald Lassagne, Senior Director, LivaNova, on Saturday, December 4 from 12-2 p.m. Central.
• "Healthcare Costs Associated with Vagus Nerve Stimulation and Medical Treatment in Pediatric Patients with Refractory Epilepsy: A Comparison of 2 Cohorts." Presented by Lu Zhang, Ph.D., Postdoctoral Fellow, Division of Pediatric Neurosurgery, Ann and Robert H. Lurie Children's Hospital of Chicago, on Sunday, December 5 from 12-2 p.m. Central.
• "CORE-VNS: A Prospective Outcomes Registry of People with Drug-Resistant Epilepsy Treated with Vagus Nerve Stimulation Therapy – Full Cohort Demographics." Presented by Massimiliano Boffini, Ph.D., Neuromodulation Senior Medical Science Liaison, LivaNova, on Sunday, December 5 from 12-2 p.m. Central.
• "Does Response to Vagus Nerve Stimulation for Drug-Resistant Epilepsy Differ in Patients with and without Lennox-Gastaut Syndrome (LGS)?" Presented by Maxine Dibué, Ph.D., Neuromodulation Medical Affairs Director, LivaNova, on Monday, December 6 from 12-1:45 p.m. Central.
• "Patient Profiles in Drug-Resistant Epilepsy (DRE): Vagus Nerve Stimulation (VNS) vs. Responsive Neurostimulation (RNS)/Deep Brain Stimulation (DBS)." Presented by Reginald Lassagne, Senior Director, LivaNova, on Monday, December 6 from 12-1:45 p.m. Central.
• "Use of Data Mining and a Generalized Linear Mixed Model to Identify Optimal Vagus Nerve Stimulation and Titration for Patients with Drug-Resistant Epilepsy." Presented by Ryan S. Verner, Ph.D., Neuromodulation Clinical Strategy Manager, LivaNova, on Monday, December 6 from 12-1:45 p.m. Central.
• "Vagus Nerve Stimulation (VNS) in Genetic Epilepsies: An Update from Highly Specialized Centers Around the World." Presented by Gaia Giannicola, Ph.D., Clinical Project Manager, LivaNova, on Monday, December 6 from 12-1:45 p.m. Central.

The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients 4 years of age and older with partial onset seizures that are refractory to antiepileptic medications. VNS Therapy is designed to prevent seizures before they occur and stop them if they do. It is a unique treatment approach developed for people with drug-resistant epilepsy—a condition that affects one in three people with epilepsy. VNS Therapy has not been evaluated by the FDA for use in LGS patients specifically. Commonly reported side effects are hoarseness, shortness of breath, sore throat and coughing. Side effects typically occur during stimulation and are less noticeable over time. For more information, visit www.VNSTherapy.com/safety.

LivaNova PLC is a global medical technology and innovation company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 3,000 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. For more information, please visit www.livanova.com.

This news release contains "forward-looking statements" concerning our goals, beliefs, expectations, strategies, objectives, plans and underlying assumptions and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding participation in upcoming events and VNS Therapy for drug-resistant epilepsy. Actual results may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2020, as supplemented by any risk factors contained in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. We undertake no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.